Michael J. Currens

TL;DR: The new XTT reagent provides for a simplified, in vitro cell growth assay with possible applicability to a variety of problems in cellular pharmacology and biology, but still shares many of the limitations and potential pitfalls of MTT or other tetrazolium-based assays.

TL;DR: Calanolide A was active not only against the AZT-resistant G-9106 strain of HIV-1 but also against the pyridinone-resistant A17 strain, which was of particular interest since the A17 virus is highly resistant to previously known HIV- 1 specific, non-nucleoside RT inhibitors.

TL;DR: Analysis of mutants used to analyze calanolide A, 1H,3H-thiazolo[3,4-a]benzimidazole(4i), and the acyclic nucleoside analog 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine suggest that all three drugs interact with HIV-1 RT within the previously defined common binding site for nonnucleoside inhibitors.

TL;DR: The application of high-throughput screening to anti-cancer drug discovery, with special reference to approaches used at the U.S. National Cancer Institute is discussed.

TL;DR: Circular dichroism studies additionally illuminated the binding of CV-N with both sgp120 and sgp41, providing the first direct evidence that conformational changes are a consequence ofCV-N interactions with both HIV-1 envelope glycoproteins.